Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2
- 15 February 2005
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (4), 863-867
- https://doi.org/10.1016/j.bmcl.2004.12.073
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Wagging the Dogma: Tissue-Specific Cell Cycle Control in the Mouse EmbryoCell, 2004
- P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in ratsCancer Chemotherapy and Pharmacology, 2004
- Cdk1: Unsung Hero of S Phase?Cell Cycle, 2004
- N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentJournal of Medicinal Chemistry, 2004
- Recycling the Cell Cycle: Cyclins RevisitedCell, 2004
- Cell Proliferation without Cyclin E-CDK2Cell, 2003
- Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical TrialsAccounts of Chemical Research, 2003
- Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical DevelopmentAnnals of Pharmacotherapy, 2002
- Structure-based design of cyclin-dependent kinase inhibitorsPharmacology & Therapeutics, 2002
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990